A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Christopher L. Bowlus; Michael R. Galambos; Richard J. Aspinall; Gideon M. Hirschfield; David E.J. Jones; Yvonne Dörffel; Stuart C. Gordon; Stephen A. Harrison; Andreas E. Kremer; Marlyn J. Mayo; Paul J. Thuluvath; Cynthia Levy; Mark G. Swain; Guy W. Neff; David A. Sheridan; Carmen M. Stanca; Christoph P. Berg; Aparna Goel; Mitchell L. Shiffman; John M. Vierling; Pol Boudes; Alexandra Steinberg; Yun Jung Choi; Charles A. McWherter

doi:10.1016/j.jhep.2022.02.033

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Christopher L. Bowlus^*
, Michael R. Galambos
, Richard J. Aspinall
, Gideon M. Hirschfield
, David E.J. Jones
, Yvonne Dörffel
, Stuart C. Gordon
, Stephen A. Harrison
, Andreas E. Kremer
, Marlyn J. Mayo
, Paul J. Thuluvath
, Cynthia Levy
, Mark G. Swain
, Guy W. Neff
, David A. Sheridan
, Carmen M. Stanca
, Christoph P. Berg
, Aparna Goel
, Mitchell L. Shiffman
, John M. Vierling

Pol Boudes, Alexandra Steinberg, Yun Jung Choi, Charles A. McWherter

^*Corresponding author for this work

Peninsula Medical School

University of California at Davis
Piedmont Atlanta Hospital
Portsmouth Hospitals University NHS Trust
University Health Network University of Toronto
Newcastle University
Charité Universitätsmedizin Berlin
Henry Ford Health System
Pinnacle Clinical Research
University of Oxford
Friedrich-Alexander University Erlangen-Nürnberg
University of Zurich
University of Texas Southwestern Medical Center
Mercy Medical Center Baltimore
University of Maryland, Baltimore
University of Miami
University of Calgary
LLC
University Hospitals Plymouth NHS Trust
New York University
University of Tübingen
Stanford University
Liver Institute of Virginia
Baylor College of Medicine
Inc.

Research output: Contribution to journal › Article › peer-review

19 Downloads (Pure)

Original language	English
Number of pages	0
Journal	Journal of Hepatology
Volume	0
Issue number	0
Early online date	30 Mar 2022
DOIs	https://doi.org/10.1016/j.jhep.2022.02.033
Publication status	Published - 30 Mar 2022

Access to Document

10.1016/j.jhep.2022.02.033

1-s2Final published version, 9.18 MB

Cite this

Bowlus, C. L., Galambos, M. R., Aspinall, R. J., Hirschfield, G. M., Jones, D. E. J., Dörffel, Y., Gordon, S. C., Harrison, S. A., Kremer, A. E., Mayo, M. J., Thuluvath, P. J., Levy, C., Swain, M. G., Neff, G. W., Sheridan, D. A., Stanca, C. M., Berg, C. P., Goel, A., Shiffman, M. L., ... McWherter, C. A. (2022). A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. Journal of Hepatology, 0(0). https://doi.org/10.1016/j.jhep.2022.02.033

@article{9cc1f46179ea481ba5c0e5bb7c0e8f07,

title = "A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis",

author = "Bowlus, \{Christopher L.\} and Galambos, \{Michael R.\} and Aspinall, \{Richard J.\} and Hirschfield, \{Gideon M.\} and Jones, \{David E.J.\} and Yvonne D{\"o}rffel and Gordon, \{Stuart C.\} and Harrison, \{Stephen A.\} and Kremer, \{Andreas E.\} and Mayo, \{Marlyn J.\} and Thuluvath, \{Paul J.\} and Cynthia Levy and Swain, \{Mark G.\} and Neff, \{Guy W.\} and Sheridan, \{David A.\} and Stanca, \{Carmen M.\} and Berg, \{Christoph P.\} and Aparna Goel and Shiffman, \{Mitchell L.\} and Vierling, \{John M.\} and Pol Boudes and Alexandra Steinberg and Choi, \{Yun Jung\} and McWherter, \{Charles A.\}",

year = "2022",

month = mar,

day = "30",

doi = "10.1016/j.jhep.2022.02.033",

language = "English",

volume = "0",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "0",

}

Bowlus, CL, Galambos, MR, Aspinall, RJ, Hirschfield, GM, Jones, DEJ, Dörffel, Y, Gordon, SC, Harrison, SA, Kremer, AE, Mayo, MJ, Thuluvath, PJ, Levy, C, Swain, MG, Neff, GW, Sheridan, DA, Stanca, CM, Berg, CP, Goel, A, Shiffman, ML, Vierling, JM, Boudes, P, Steinberg, A, Choi, YJ & McWherter, CA 2022, 'A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis', Journal of Hepatology, vol. 0, no. 0. https://doi.org/10.1016/j.jhep.2022.02.033

TY - JOUR

T1 - A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

AU - Bowlus, Christopher L.

AU - Galambos, Michael R.

AU - Aspinall, Richard J.

AU - Hirschfield, Gideon M.

AU - Jones, David E.J.

AU - Dörffel, Yvonne

AU - Gordon, Stuart C.

AU - Harrison, Stephen A.

AU - Kremer, Andreas E.

AU - Mayo, Marlyn J.

AU - Thuluvath, Paul J.

AU - Levy, Cynthia

AU - Swain, Mark G.

AU - Neff, Guy W.

AU - Sheridan, David A.

AU - Stanca, Carmen M.

AU - Berg, Christoph P.

AU - Goel, Aparna

AU - Shiffman, Mitchell L.

AU - Vierling, John M.

AU - Boudes, Pol

AU - Steinberg, Alexandra

AU - Choi, Yun Jung

AU - McWherter, Charles A.

PY - 2022/3/30

Y1 - 2022/3/30

UR - https://pearl.plymouth.ac.uk/pms-research/298/

U2 - 10.1016/j.jhep.2022.02.033

DO - 10.1016/j.jhep.2022.02.033

M3 - Article

SN - 0168-8278

VL - 0

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 0

ER -

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Access to Document

Other files and links

Cite this